Tevogen Bio (NASDAQ:TVGN – Get Free Report) is projected to release its results before the market opens on Friday, November 13th. Analysts expect Tevogen Bio to announce earnings of ($2.5550) per share for the quarter.
Tevogen Bio (NASDAQ:TVGN – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($1.52) EPS for the quarter, beating the consensus estimate of ($2.53) by $1.01.
Tevogen Bio Price Performance
TVGN stock opened at $5.72 on Wednesday. Tevogen Bio has a 52 week low of $3.64 and a 52 week high of $24.91. The company’s 50-day moving average price is $6.83 and its 200 day moving average price is $7.90.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a report on Thursday, October 15th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tevogen Bio has an average rating of “Reduce” and a consensus price target of $100.00.
View Our Latest Report on Tevogen Bio
About Tevogen Bio
Tevogen Bio is a clinical-stage biotechnology company focused on developing off-the-shelf T-cell therapies for patients with viral infections, cancer and other serious medical conditions. Its approach is designed to use virus-specific cytotoxic T lymphocytes to target diseased cells while limiting the challenges associated with individualized cell therapies. The company’s lead program, TVGN 489, is an investigational T-cell therapy intended to address COVID-19 and other conditions caused by SARS-CoV-2, particularly among immunocompromised patients.
Read More
- Five stocks we like better than Tevogen Bio
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
